Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.

In that study, the 3-year PFS rate was 66.3% in the group that received DOS therapy and 60.2% in the group that received surgery plus postoperative S-1 therapy, indicating a favorable trend for the preoperative group [ 9 ].

also in 932 other papers

However, patients with ESCC were also included in that study, and subgroup analysis by histological subtype showed a trend toward worse OS in those with EAC than in those with ESCC.

also in 28,865 other papers